Company Analysis
Sign in

Arcturus Therapeutics Holdings Inc. (ARCT)

Nasdaq: ARCT · Pharmaceutical Preparations · San Diego, CA · filing with the SEC since 2019
Full chart Alerts Compare
Grade5.3
◀ Past 5.7● Present 6.2▶ Future 3.9
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

61 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Arcturus Therapeutics Holdings Inc.’s names, not what it holds today.

Patents granted
61
59 utility, 2 reissue, 1976 to Dec 31, 2025
Granted in 2025
9
Against 7 in 2024 and 5 in 2023
Applications published
91
7 of them in 2025
Names they are printed under
2
a subsidiary
By yearGrantedApplications published
'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals19
Biotechnology4
Organic fine chemistry3
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Arcturus Therapeutics, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
90 published
Arcturus Therapeutics, Inc. a subsidiary
US, as the owner printed on each patent
61 granted
1 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 30, 202512,509,698Synthesis and structure of high potency RNA therapeuticsBiotechnologyArcturus Therapeutics, Inc.
Dec 2, 2025RE50,681Ionizable cationic lipid for RNA deliveryArcturus Therapeutics, Inc.
Aug 26, 202512,398,379Compositions and methods for treating ornithine transcarbamylase deficiencyPharmaceuticalsArcturus Therapeutics, Inc.
Aug 19, 202512,390,524Compositions and methods for inducing immune responsesPharmaceuticalsArcturus Therapeutics, Inc.
Jul 8, 202512,351,834Compositions and methods for the treatment of ornithine transcarbamylase deficiencyPharmaceuticalsArcturus Therapeutics, Inc.
May 6, 202512,290,567Asialoglycoprotein Receptor mediated delivery of therapeutically active conjugatesOrganic fine chemistryArcturus Therapeutics, Inc.
Apr 29, 202512,286,395Method of synthesis of an ionizable cationic lipidOrganic fine chemistryArcturus Therapeutics, Inc.
Feb 11, 202512,220,485Method of making lipid-encapsulated RNA nanoparticlesPharmaceuticalsArcturus Therapeutics, Inc.
Feb 11, 202512,220,455Coronavirus vaccine compositions and methodsPharmaceuticalsArcturus Therapeutics, Inc.
Dec 31, 202412,178,921Method of lyophilizing lipid nanoparticlesPharmaceuticalsArcturus Therapeutics, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Oct 2, 20252025/0304532METHOD OF SYNTHESIS OF AN IONIZABLE CATIONIC LIPIDOrganic fine chemistryArcturus Therapeutics, Inc.
Jul 3, 20252025/0213495METHOD OF LYOPHILIZING LIPID NANOPARTICLESPharmaceuticalsArcturus Therapeutics, Inc.
Jun 5, 20252025/0177305METHOD OF MAKING LIPID-ENCAPSULATED RNA NANOPARTICLESPharmaceuticalsArcturus Therapeutics, Inc.
May 22, 20252025/0161434CORONAVIRUS VACCINE COMPOSITIONS AND METHODSPharmaceuticalsArcturus Therapeutics, Inc.
May 1, 20252025/0136953COMPOSITIONS AND METHODS FOR THE TREATMENT OF ORNITHINE TRANSCARBAMYLASE DEFICIENCYPharmaceuticalsArcturus Therapeutics, Inc.
Feb 13, 20252025/0049950NUCLEIC ACIDS AND METHODS OF TREATMENT FOR CYSTIC FIBROSISPharmaceuticalsArcturus Therapeutics, Inc.
Jan 2, 20252025/0000957COMPOSITIONS AND METHODS FOR TREATING PHENYLKETONURIAPharmaceuticalsArcturus Therapeutics, Inc.
Nov 28, 20242024/0391870IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERYOrganic fine chemistryArcturus Therapeutics, Inc.
Sep 26, 20242024/0316090TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR NUCLEASES (TALENS) TARGETING HBVBiotechnologyArcturus Therapeutics, Inc.
Sep 19, 20242024/0309366COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERSPharmaceuticalsArcturus Therapeutics, Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 12 · Biotechnology 2 · Organic fine chemistry 2.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton ARCT · research, not advice